SCHEMBL28022048

SCHEMBL28022048

CC(=O)Nc1ccc(S(=O)(=O)c2nccc(Nc3cc(C)n[nH]3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 2/20 0.46
▸ AURKB Q96GD4 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ PAX8 Q06710 1/20 0.44
▸ PKM P14618 2/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ APOBEC3A P31941 1/20 0.39
▸ APOBEC3G Q9HC16 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ MMP1 P03956 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28022078 0.84 PKM (0.44) AURKAAURKBALDH1A1KDM4EPAX8
SCHEMBL28557357 0.82 AURKB (0.49) AURKAAURKBALDH1A1KDM4EPKM
SCHEMBL28022063 0.80 SMN1; SMN2 (0.42) AURKAAURKBALDH1A1KDM4EPOLB
SCHEMBL28556178 0.80 AURKA (0.39) AURKAAURKBALDH1A1KDM4EPKM
SCHEMBL28549342 0.79 ACHE (0.48) AURKAAURKBALDH1A1KDM4EPOLB
SCHEMBL28021607 0.79 SLC2A1 (0.44) ALDH1A1KDM4ECYP2C19MAPT
SCHEMBL2205314 0.78 AURKA (0.73) AURKAAURKBL3MBTL1APOBEC3AAPOBEC3G
SCHEMBL28022056 0.78 PIK3CA (0.46) AURKAAURKBPOLBL3MBTL1MAPT
SCHEMBL28022120 0.75 MEN1 (0.39) AURKAAURKBALDH1A1KDM4EPKM
SCHEMBL28570362 0.75 RET (0.43) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112755193-A Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof 德玛医药 2021-05-07 — — CN disclosed
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 — — CN disclosed
Send feedback